Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, Bin, Zhang, Qi, Ge, Jiwan, Wang, Ruoke, Sun, Jing, Ge, Xiangyang, Yu, Jiazhen, Shan, Sisi +16 more·2020·Nature
DOI 10.1038/s41586-020-2380-z

Cited by (1,008)

Items 201–300 of 1,008

  1. Computational epitope map of SARS-CoV-2 spike protein
    Mateusz Sikora, Sören von Bülow, Florian E.C. Blanc, Michael Gecht, Roberto Covino, Gerhard Hummer · 2021 · PLoS Computational Biology
  2. Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation
    D. W. Chen, Chue Vin Chin, Devin Kenney, Alexander H. Tavares, Nazimuddin Khan, Hasahn L. Conway, Guanqun Liu, Manish Chandra Choudhary, Hans P. Gertje, Aoife Kateri O’Connell et al. · 2023 · Nature
  3. COVID-19: Mechanisms of Vaccination and Immunity
    Daniel E. Speiser, Martin F. Bachmann · 2020 · Vaccines
  4. Particulate Alum via Pickering Emulsion for an Enhanced COVID‐19 Vaccine Adjuvant
    Sha Peng, Fengqiang Cao, Yufei Xia, Xiao‐Dong Gao, Lianpan Dai, Jinghua Yan, Guanghui Ma · 2020 · Advanced Materials
  5. HLA, Immune Response, and Susceptibility to COVID-19
    Fataneh Tavasolian, Mohsen Rashidi, Gholamreza Hatam, Marjan Jeddi, Ahmad Zavaran Hosseini, Sayed Hussain Mosawi, Elham Abdollahi, Robert Davies Inman · 2021 · Frontiers in Immunology
  6. Dengue Fever, COVID ‐19 ( SARS‐CoV ‐2), and Antibody‐Dependent Enhancement ( ADE ): A Perspective
    Henning Ulrich, Micheli Mainardi Pillat, Attila Tárnok · 2020 · Cytometry Part A
  7. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
    Savannah E. Butler, Andrew R. Crowley, Harini Natarajan, Shiwei Xu, Joshua A. Weiner, Carly A. Bobak, Daniel E. Mattox, Jiwon Lee, Wendy Wieland‐Alter, Ruth I. Connor et al. · 2021 · Frontiers in Immunology
  8. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry
    Julián Valero, Laia Civit, D. M. Dupont, Denis Selnihhin, Line S. Reinert, M. Idorn, Brett A. Israels, Aleksandra Bednarz, C. Bus, B. Asbach et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  9. GenSLMs: Genome-scale language models reveal SARS-CoV-2 evolutionary dynamics
    Zvyagin, Maxim, Brace, Alexander, Hippe, Kyle, Deng, Yuntian, Zhang, Bin, Bohorquez, Cindy Orozco, Clyde, Austin, Kale, Bharat, Perez-Rivera, Danilo, Ma, Heng et al. · 2023 · The International Journal of High Performance Computing Applications
  10. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
    P. Tong, Avneesh Gautam, I. Windsor, M. Travers, Yuezhou Chen, Nicholas Garcia, Noah B. Whiteman, Lindsay G. A. McKay, N. Storm, Lauren E. Malsick et al. · 2021 · Cell
  11. GenSLMs: Genome-scale language models reveal SARS-CoV-2 evolutionary dynamics
    Zvyagin, Maxim, Brace, Alexander, Hippe, Kyle, Deng, Yuntian, Zhang, Bin, Bohorquez, Cindy Orozco, Clyde, Austin, Kale, Bharat, Perez-Rivera, Danilo, Ma, Heng et al. · 2022
  12. Scientific research progress of COVID‐19/SARS‐CoV‐2 in the first five months
    Hua Li, Zhe Liu, Junbo Ge · 2020 · Journal of Cellular and Molecular Medicine
  13. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
    Pedro Antonio Reche · 2020 · Frontiers in Immunology
  14. Neutralizing antibodies for the treatment of COVID-19
    Shi-Bo Jiang, Xiujuan Zhang, Yang Yang, P. Hotez, L. Du · 2020 · Nature Biomedical Engineering
  15. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
    Linling He, Xiaohe Lin, Ying Wang, Ciril Abraham, Cindy Sou, Timothy Ngo, Yi Zhang, Ian A. Wilson, Jiang Zhu · 2021 · Science Advances
  16. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
    Yuwen Zhou, Yao Xie, Liansha Tang, Dan Pu, Yajuan Zhu, Jiyan Liu, Xuelei Ma · 2021 · Signal Transduction and Targeted Therapy
  17. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
    Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, Jérémie Prévost, William David Tolbert, Kelly Symmes, Shilei Ding, Mehdi Benlarbi, Shang Yu Gong, Alexandra Tauzin et al. · 2022 · Cell Reports
  18. A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination
    Guofang Zhang, Yalin Cong, Feng‐Liang Liu, Jiufeng Sun, Jiantian Zhang, Guoli Cao, Lingqiang Zhou, Wenjie Yang, Qingle Song, Fangjun Wang et al. · 2022 · Nature Nanotechnology
  19. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2
    Alex Renn, Ying Fu, Xin Hu, Matthew D. Hall, Anton M. Simeonov · 2020 · Trends in Pharmacological Sciences
  20. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays
    Maria Giaele Infantino, Massimo Pieri, Marzia Nuccetelli, Valentina Grossi, Barbara Lari, Flaminia Tomassetti, Graziella Calugi, Silvia Pancani, Maurizio Benucci, Patrizia Casprini et al. · 2021 · International Immunopharmacology
  21. Disease diagnostics using machine learning of B cell and T cell receptor sequences
    Maxim Zaslavsky, Erin Craig, Jackson Michuda, Nidhi Sehgal, Nikhil Ram-Mohan, Ji-Yeun Lee, Khoa D. Nguyen, Ramona A. Hoh, Tho D. Pham, Katharina Röltgen et al. · 2025 · Science
  22. Approaches and Challenges in SARS-CoV-2 Vaccine Development
    Dagotto, Gabriel, Yu, Jingyou, Barouch, Dan H. · 2020 · Cell Host & Microbe
  23. Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis
    Kirill Gorshkov, Kimihiro Susumu, Jiji Chen, Miao Xu, Manisha Pradhan, Wei Zhu, Xin Hu, Joyce C. Breger, Mason A. Wolak, Eunkeu Oh · 2020 · ACS Nano
  24. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
    Mattia Tiboni, Luca Casettari, Lisbeth Illum · 2021 · International Journal of Pharmaceutics
  25. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
    Wei Li, Alexandra Schäfer, Swarali S. Kulkarni, Xianglei Liu, David R. Martinez, Chuan Chen, Zehua Sun, Sarah R. Leist, Aleksandra K. Drelich, Liyong Zhang et al. · 2020 · Cell
  26. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
    Jorge Carrillo, Nuria Izquierdo‐Useros, Carlos Ávila‐Nieto, Edwards Pradenas, Bonaventura Clotet, Julià Blanco · 2020 · Biochemical and Biophysical Research Communications
  27. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
    H. M. Mengist, Arnaud John Kombe Kombe, D. Mekonnen, Abtie Abebaw, Melese Getachew, Teng-Chuan Jin · 2021 · Seminars in Immunology
  28. Neutralizing antibodies targeting SARS-CoV-2 spike protein
    Xiao-Jie Shi, Li Yu, Yan Lei, Yang Guang, Qiang Min · 2020 · Stem Cell Research
  29. Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course
    Rashika Bansal, Sriram Gubbi, Ranganath Muniyappa · 2020 · Endocrinology
  30. Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies
    Jiahui Chen, Kaifu Gao, Rui Wang, Guo‐Wei Wei · 2021 · Chemical Science
  31. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
    Qian Wang, Sho Iketani, Zhiteng Li, Yicheng Guo, Andre Yanchen Yeh, Michael Liu, Jian Yu, Zizhang Sheng, Yaoxing Huang, Lihong Liu et al. · 2022 · Cell Host & Microbe
  32. Current Strategies of Antiviral Drug Discovery for COVID-19
    Miao Mei, Xu Tan · 2021 · Frontiers in Molecular Biosciences
  33. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines
    Hsin‐I Shih, Chi-Jung Wu, Yi‐Fang Tu, Chia‐Yu Chi · 2020 · Biomedical Journal
  34. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States
    David Alfego, Adam Sullivan, Brian Poirier, Jonathan Williams, Ajay Grover, Laura Gillim, Dorothy M. Adcock, Stanley I. Letovsky · 2021 · EClinicalMedicine
  35. Cryo-EM structure of the SARS-CoV-2 Omicron spike
    Gabriele Cerutti, Yicheng Guo, Lihong Liu, Liyuan Liu, Zhening Zhang, Yang Luo, Yiming Huang, Harris H. Wang, David D. Ho, Zizhang Sheng et al. · 2022 · Cell Reports
  36. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
    Ting-Yi Li, H. Cai, H. Yao, Bingjie Zhou, Ning Zhang, Martje Fentener van Vlissingen, T. Kuiken, Wen-Yu Han, C. Geurtsvankessel, Yuhuan Gong et al. · 2021 · Nature Communications
  37. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
    Madeleine F. Jennewein, Anna J. MacCamy, N. R. Akins, Junli Feng, Leah J. Homad, N. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, A. Stuart, V. Edara et al. · 2021 · bioRxiv
  38. Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines
    Yunfeng Zheng, Renfeng Li, Shunai Liu · 2020 · Journal of Medical Virology
  39. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
    Xi-Lin Wu, Lin Cheng, Ming Fu, Bilian Huang, Lin-Jing Zhu, Shijie Xu, Haixia Shi, Dou-Dou Zhang, Huanyun Yuan, Waqas Nawaz et al. · 2021 · bioRxiv
  40. Contribution of STAT3 to the pathogenesis of COVID-19
    Abdollah Jafarzadeh, Maryam Nemati, Sara Jafarzadeh · 2021 · Microbial Pathogenesis
  41. Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
    Rui Wang, Jiahui Chen, Guo‐Wei Wei · 2021 · The Journal of Physical Chemistry Letters
  42. Animal models for COVID-19: advances, gaps and perspectives
    Changfa Fan, Yong Wu, Rui Xiong, Yuansong Yang, Chen Ling, Susu Liu, Shunan Liu, Youchun Wang · 2022 · Signal Transduction and Targeted Therapy
  43. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19
    Lifei Yang, Weihan Liu, Xin Yu, Meng Wu, Janice M. Reichert, Mitchell Ho · 2020 · Antibody Therapeutics
  44. The immunology of SARS-CoV-2 infections and vaccines
    Lilit Grigoryan, B. Pulendran · 2020 · Seminars in Immunology
  45. Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production
    Xiaohui Zhao, Huan Chen, Hongliang Wang · 2021 · Frontiers in Molecular Biosciences
  46. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
    Katarina Resman Rus, Miša Korva, Nataša Knap, Tatjana Avšič‐Županc, Mario Poljak · 2021 · Journal of Clinical Virology
  47. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
    Marloes Grobben, Karlijn van der Straten, Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre‐Bosquet, Brent Appelman, A. H. Ayesha Lavell, Lonneke A. van Vught, Judith A. Burger et al. · 2021 · eLife
  48. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19
    Gregory D. Sempowski, Kevin O. Saunders, Priyamvada Acharya, Kevin J. Wiehe, Barton F. Haynes · 2020 · Cell
  49. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
    Chao Zhang, Yifan Wang, Yuanfei Zhu, Caixuan Liu, Chenjian Gu, Shiqi Xu, Yalei Wang, Yu Zhou, Yanxing Wang, Wenyu Han et al. · 2021 · Nature Communications
  50. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
    Marta Alenquer, Filipe Ferreira, Diana Lousa, Mariana Valério, Mónica Medina-Lopes, Marie‐Louise Bergman, Juliana Gonçalves, Jocelyne Demengeot, Ricardo B. Leite, Jingtao Lilue et al. · 2021 · PLoS Pathogens
  51. Current Status of COVID-19 Therapies and Drug Repositioning Applications
    Altay, Ozlem, Mohammadi, Elyas, Lam, Simon, Turkez, Hasan, Boren, Jan, Nielsen, Jens, Uhlen, Mathias, Mardinoglu, Adil · 2020 · iScience
  52. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
    Stamatatos, Leonidas, Czartoski, Julie, Wan, Yu-Hsin, Homad, Leah J., Rubin, Vanessa, Glantz, Hayley, Neradilek, Moni, Seydoux, Emilie, Jennewein, Madeleine F., MacCamy, Anna J. et al. · 2021
  53. Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape
    Miao Sun, Siwen Liu, Ting Song, Fude Chen, Jialü Zhang, Jia-ao Huang, Shuang Wan, Yao Wei W Lu, Honglin Chen, Weihong Tan et al. · 2021 · Journal of the American Chemical Society
  54. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
    Song, Ge, He, Wan-ting, Callaghan, Sean, Anzanello, Fabio, Huang, Deli, Ricketts, James, Torres, Jonathan L., Beutler, Nathan, Peng, Linghang, Vargas, Sirena et al. · 2020
  55. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
    Crystal Y. Zheng, Indrani Kar, Claire Kaori Chen, Crystal Sau, Sophia Woodson, Alessandro Serra, Hesham Abboud · 2020 · CNS Drugs
  56. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
    Anton M. Sholukh, A. Fiore-Gartland, E. S. Ford, Maurine D. Miner, Y. Hou, Long-Ping V. Tse, Hannah Kaiser, Haiying Zhu, Joyce Y. C. Lu, Bhanupriya Madarampalli et al. · 2021 · Journal of Clinical Microbiology
  57. Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor
    Jinbiao Liu, Brittany H. Bodnar, Fengzhen Meng, Adil I. Khan, Xu Wang, Guangxiang George Luo, Sami Saribas, Tao Wang, Saroj Chandra Lohani, Peng Wang et al. · 2021 · Cell & Bioscience
  58. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
    A. Deshpande, Bethany D. Harris, L. Martínez-Sobrido, J. Kobie, M. Walter · 2021 · bioRxiv
  59. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
    Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abassi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke et al. · 2021 · Cell Reports
  60. Molecularly Imprinted Polymer Nanoparticles Enable Rapid, Reliable, and Robust Point-of-Care Thermal Detection of SARS-CoV-2
    Jake McClements, Laure Bar, Pankaj Singla, Francesco Canfarotta, Alan Thomson, Joanna Czulak, Rhiannon Johnson, Robert D. Crapnell, Craig Edward Banks, Brendan A. I. Payne et al. · 2022 · ACS Sensors
  61. Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection
    Liang Guo, Wenwen Bi, Xinling Wang, Wei Xu, Renhong Yan, Yuanyuan Zhang, Kai Zhao, Yaning Li, Mingfeng Zhang, Xia Cai et al. · 2020 · Cell Research
  62. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding
    Dhiraj Mannar, James W. Saville, Xing Quan Zhu, Shanti Swaroop Srivastava, Alison Berezuk, Steven Zhou, Katharine S. Tuttle, Andrew Kim, Wei Li, Dimiter Stanchev Dimitrov et al. · 2021 · Cell Reports
  63. SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen
    Yunfei Wang, Lichun Wang, Han Cao, Cunbao Liu · 2020 · Journal of Medical Virology
  64. Immunobiology and immunotherapy of COVID‐19: A clinically updated overview
    Abdolreza Esmaeilzadeh, Reza Elahi · 2020 · Journal of Cellular Physiology
  65. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
    Anastassios C. Papageorgiou, Imran Mohsin · 2020 · Cells
  66. Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone
    Cheng Wang, Shaobo Wang, Daixi Li, Peiqin Chen, Songling Han, Gaomei Zhao, Yin Chen, Jianqi Zhao, Jiachuan Xiong, Jingfei Qiu et al. · 2021 · ACS Infectious Diseases
  67. Mutation-induced Changes in the Receptor-binding Interface of the SARS-CoV-2 Delta Variant B.1.617.2 and Implications for Immune Evasion
    Prabin Baral, Nisha Bhattarai, Md Lokman Hossen, Vitalii Stebliankin, Bernard S. Gerstman, Giri Narasimhan, Prem P. Chapagain · 2021 · Biochemical and Biophysical Research Communications
  68. New drug discovery and development from natural products: Advances and strategies
    Yixin Wang, Fan Wang, Wenxiu Liu, Yifei Geng, Yahong Shi, Tian Yu, Bin Zhang, Yun Luo, Xiaobo Sun · 2024 · Pharmacology & Therapeutics
  69. Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications
    Xueran Xiao, Hui Li, Lijian Zhao, Yanfen Zhang, Zhongcheng Liu · 2021 · Biomedicine & Pharmacotherapy
  70. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
    Annika Fendler, Lewis Au, Scott T.C. Shepherd, Fiona Byrne, Maddalena Cerrone, Laura Amanda Boos, Karolina Rzeniewicz, William Gordon, Benjamin Shum, Camille Lea Gerard et al. · 2021 · Nature Cancer
  71. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
    Carlos A Cruz-Teran, Karthik Tiruthani, Morgan D. McSweeney, Alice D. Ma, R. Pickles, S. Lai · 2020 · Advanced Drug Delivery Reviews
  72. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases
    To Sing Fung, Ding Xiang Liu · 2021 · Annual Review of Microbiology
  73. Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
    Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, ARTO A. I. PALMU, Merit M. Melin · 2021 · European Journal of Immunology
  74. Immune response following infection with SARS‐CoV ‐2 and other coronaviruses: A rapid review
    Éamon Ó Murchú, Paula Byrne, Kieran Anthony Walsh, Paul G. Carty, Máire A Connolly, Cillian F De Gascun, Karen Jordan, Mary Keoghan, Kirsty K O’Brien, Michelle O’Neill et al. · 2020 · Reviews in Medical Virology
  75. Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview
    Leila Mohamed Khosroshahi, Mohsen Rokni, Tahmineh Mokhtari, Farshid Noorbakhsh · 2021 · International Immunopharmacology
  76. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
    N. C. Dalvie, Sergio A. Rodriguez-Aponte, B. Hartwell, Lisa H. Tostanoski, Andrew M. Biedermann, Laura E. Crowell, K. Kaur, Ozan S. Kumru, L. Carter, Jing-You Yu et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  77. Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives
    Heba A. Hussein, Rabeay Y. A. Hassan, Marco Chino, Ferdinando Febbraio · 2020 · Sensors
  78. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19
    Liis Haljasmägi, Ahto Salumets, Anna Pauliina Rumm, Meeri Jürgenson, Ekaterina Krassohhina, Anu Remm, Hanna Sein, Lauri Kareinen, Olli P. Vapalahti, Tarja A. Sironen et al. · 2020 · Scientific Reports
  79. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
    Sisi Kang, Mei Yang, Suhua He, Yueming Wang, Xiaoxue Chen, Yao-Qing Chen, Zhongsi Hong, Jing Liu, Guanmin Jiang, Qiuyue Chen et al. · 2021 · Nature Communications
  80. COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
    John P. Moore, Per Johan Klasse · 2020 · Journal of Virology
  81. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract
    Fengyu Hu, Fengjuan Chen, Zhihua Ou, Qinghong Fan, Xinghua Tan, Yaping Wang, Yuejun Pan, Bixia Ke, Linghua Li, Yujuan Guan et al. · 2020 · Cellular and Molecular Immunology
  82. Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
    Vincent J. Venditto, Dalia Haydar, Ahmed Abdel‐Latif, John C. Gensel, Michael Anstead, Michelle G. Pitts, Jarrod W. Creameans, Timothy Joseph Kopper, Chi Peng, David J. Feola · 2021 · Frontiers in Immunology
  83. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
    Tingting Li, Wenhui Xue, Qingbing Zheng, Shuo Song, Chuanlai Yang, Hualong Xiong, Sibo Zhang, Minqing Hong, Yali Zhang, Hai Jing Yu et al. · 2021 · Nature Communications
  84. Overview of Neutralizing Antibodies and Their Potential in COVID-19
    José Javier Morales‐Núñez, José Francisco Muñóz-Valle, Paola Carolina Torres-Hernández, Jorge Hernández‐Bello · 2021 · Vaccines
  85. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
    Edem Gavor, Yeu Khai Choong, Shi Yin Er, Hariharan Sivaraman, Jayaraman Sivaraman · 2020 · Trends in Immunology
  86. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
    Wei Li, Chuan Chen, Aleksandra K. Drelich, David R. Martinez, Lisa E. Gralinski, Zehua Sun, Alexandra Schäfer, Swarali S. Kulkarni, Xianglei Liu, Sarah R. Leist et al. · 2020 · Proceedings of the National Academy of Sciences
  87. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D
    Ming-Yieh Peng, Wen-Chih Liu, Jing-Quan Zheng, Chien‐Lin Lu, Yi‐Chou Hou, Cai‐Mei Zheng, Jenn-Yeu Song, Kuo‐Cheng Lu, You‐Chen Chao · 2021 · International Journal of Molecular Sciences
  88. Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq
    Bing He, Shuning Liu, Yuanyuan Wang, Mengxin Xu, Wei Cai, Jia Liu, Wendi Bai, Shupei Ye, Yong Ma, Hengrui Hu et al. · 2021 · Signal Transduction and Targeted Therapy
  89. Therapeutic potential of ginger against COVID-19: Is there enough evidence?
    Abdollah Jafarzadeh, Sara Jafarzadeh, Maryam Nemati · 2021 · Journal of Traditional Chinese Medical Sciences
  90. Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM
    Yifan Wang, Cong Xu, Yanxing Wang, Hong Qin, Chao Zhang, Zuyang Li, Shiqi Xu, Qinyu Zuo, Caixuan Liu, Zhong Wei Huang et al. · 2021 · Nature Communications
  91. A global picture: therapeutic perspectives for COVID-19
    V. Chavda, C. Kapadia, Shailvi Soni, R. Prajapati, S. Chauhan, M. Yallapu, V. Apostolopoulos · 2022 · Immunotherapy
  92. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
    Tan, Timothy J. C., Yuan, Meng, Kuzelka, Kaylee, Padron, Gilberto C., Beal, Jacob R., Chen, Xin, Wang, Yiquan, Rivera-Cardona, Joel, Zhu, Xueyong, Stadtmueller, Beth M. et al. · 2021 · Nature Communications
  93. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV
    Ahidjo Ayouba, Guillaume Thaurignac, David Morquin, Édouard Tuaillon, Raisa Raulino, Antoine Nkuba-Ndaye, Audrey Lacroix, Nicole Vidal, Vincent Foulongne, Vincent Le Moing et al. · 2020 · Journal of Clinical Virology
  94. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals
    Sang Il Kim, Jinsung Noh, Sujeong Kim, Younggeun Choi, Duck Kyun Yoo, Yonghee Lee, Hyunho Lee, Jongtak Jung, C. K. Kang, K. Song et al. · 2021 · Science Translational Medicine
  95. The immunodominant and neutralization linear epitopes for SARS-CoV-2
    Shuai Lu, Xi-xiu Xie, Lei Zhao, Bin Wang, Jie Zhu, Ting-rui Yang, Guang-wen Yang, Mei Ji, Cui-ping Lv, Jian Xue et al. · 2021 · Cell Reports
  96. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection
    Xiao-Lin Jiang, Guo-Lin Wang, Xiang-Na Zhao, Fei-Hu Yan, Lin Yao, Z. Kou, Shengxiang Ji, Xiao-li Zhang, Cunbao Li, L. Duan et al. · 2021 · Nature Communications
  97. Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay
    Quinlin Hanson, Kelli M. Wilson, Min Shen, Zina Itkin, Richard T. Eastman, Paul Shinn, Matthew D. Hall · 2020 · ACS Pharmacology & Translational Science
  98. Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane
    Yeol Kyo Choi, Yiwei Cao, Martin Frank, Hyeonuk Woo, Sang‐Jun Park, Min Sun Yeom, Tristan Ian Croll, Chaok Seok, Wonpil Im · 2021 · Journal of Chemical Theory and Computation
  99. COVID-19—Lessons Learned and Questions Remaining
    Ferric C. Fang, Constance Ann Benson, Carlos del Rı́o, Kathryn M. Edwards, Vance G. Fowler, David N. Fredricks, Ajit P. Limaye, Barbara E. Murray, Susanna Naggie, Peter G. Pappas et al. · 2020 · Clinical Infectious Diseases
  100. Engineered cell entry links receptor biology with single-cell genomics
    Bingfei Yu, Quanming Shi, Julia A. Belk, Kathryn E. Yost, Kevin R. Parker, Rui Li, Betty B. Liu, Huang Huang, Daniel Lingwood, William James Greenleaf et al. · 2022 · Cell